Left Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low?
JACC Cardiovasc Imaging
.
2018 Aug;11(8):1094-1097.
doi: 10.1016/j.jcmg.2018.02.027.
Authors
Chau T Dang
1
,
Anne Blaes
2
,
Filipa Lynce
3
,
Sandra M Swain
3
,
Susan Dent
4
Affiliations
1
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: dangc@mskcc.org.
2
Department of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota.
3
Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.
4
Division of Medical Oncology, Department of Medicine, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada.
PMID:
30092968
DOI:
10.1016/j.jcmg.2018.02.027
No abstract available
Keywords:
breast cancer; cardiotoxicity; trastuzumab.
Publication types
Editorial
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Breast Neoplasms*
Cardiotoxicity*
Humans
Stroke Volume
Trastuzumab
Ventricular Function, Left
Substances
Trastuzumab